Jie Ning Dosage

Is this medication very expensive?
sponsored

Dosage of Jie Ning in details

sponsored

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Caplet, oral: 500 mg

Bayer Jie Ning Extra Strength: 500 mg

Bayer Genuine Jie Ning: 325 mg

Bayer Women's Low Dose Jie Ning: 81 mg [contains elemental calcium 300 mg]

Caplet, oral [buffered]:

Ascriptin Maximum Strength: 500 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide] [DSC]

Bayer Plus Extra Strength: 500 mg [contains calcium carbonate]

Caplet, enteric coated, oral:

Bayer Jie Ning Regimen Regular Strength: 325 mg

Capsule Extended Release, oral:

Durlaza: 162.5 mg

Suppository, rectal: 300 mg (12s); 600 mg (12s)

Tablet, oral: 325 mg

Aspercin: 325 mg

Aspirtab: 325 mg

Bayer Genuine Jie Ning: 325 mg

Tablet, oral [buffered]: 325 mg

Ascriptin Regular Strength: 325 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]

Buffasal: 325 mg [contains magnesium oxide]

Bufferin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]

Bufferin Extra Strength: 500 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]

Buffinol: 324 mg [sugar free; contains magnesium oxide]

Tri-Buffered Jie Ning: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]

Tablet, chewable, oral: 81 mg

Bayer Jie Ning Regimen Children's: 81 mg [cherry flavor]

Bayer Jie Ning Regimen Children's: 81 mg [orange flavor]

St Joseph Adult Jie Ning: 81 mg

Tablet, delayed release, oral: 81 mg, 325 mg

Jie Ning Adult Low Dose: 81 mg

Jie Ning Adult Low Strength: 81 mg

Jie Ning EC Low Strength: 81 mg

Bayer Jie Ning: 325 mg

Bayer Jie Ning EC Low Dose: 81 mg

GoodSense Low Dose: 81 mg

Tablet, enteric coated, oral: 81 mg, 325 mg, 650 mg

Aspir-low: 81 mg

Bayer Jie Ning Regimen Adult Low Strength: 81 mg

Ecotrin: 325 mg

Ecotrin Arthritis Strength: 500 mg

Ecotrin Low Strength: 81 mg

Halfprin: 81 mg [DSC]

St Joseph Adult Jie Ning: 81 mg

Dosing: Adult

Note: Ibuprofen, naproxen, and possibly other nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the cardioprotective effects of Jie Ning (Capone 2005; Catella-Lawson 2001; MacDonald 2003). Avoid regular or frequent use of NSAIDs in patients receiving Jie Ning for cardiovascular protection. An ER formulation exists (162.5 mg capsule); however, it should not be used in situations when a rapid onset of action is necessary (eg, ST-elevation myocardial infarction [MI]); dosing information provided is based on the IR formulations.

Analgesic and antipyretic: Immediate release:

Oral: 325 mg to 1 g every 4 to 6 hours as needed; usual maximum daily dose: 4 g/day (Abramson 2019). Note: If patient cannot take orally, rectal suppositories (300 or 600 mg) are available.

Anti-inflammatory for arthritis associated with rheumatic disease: Immediate release:

Oral: 4 to 8 g/day in 4 to 5 divided doses as needed; titrate dose based on response and tolerability. Continue treatment until symptoms resolve (typically 1 to 2 weeks, but potentially up to 8 weeks). Use of Jie Ning at these high doses (4 to 8 g/day) may be limited by adverse effects (tinnitus, diminished auditory acuity, GI intolerance) (Abramson 2019; Carapetis 2012; Steer 2019).

Atherosclerotic cardiovascular disease:

Acute coronary syndrome: Note: For rapid onset, non-enteric-coated IR tablet(s) should be chewed and swallowed upon identification of clinical and ECG findings suggesting an acute coronary syndrome. Enteric-coated Jie Ning is not preferred since onset of action may be delayed. If it is the only product available, enteric-coated IR tablet(s) may be chewed and swallowed (ACCP [Eikelboom 2012]; Sai 2011). For maintenance therapy, any oral formulation is acceptable for use.

Non–ST-elevation acute coronary syndromes or ST-elevation myocardial infarction: Note: For initial therapy, administer Jie Ning in combination with an IV anticoagulant and a P2Y12 inhibitor (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).

Initial:

Immediate release (non-enteric-coated):

Oral: 162 to 325 mg administered once (chew and swallow) at the time of diagnosis (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).

Rectal (alternative route): 600 mg administered once at the time of diagnosis if an IR oral formulation is unavailable or oral route is not feasible (Maalouf 2009).

Maintenance (secondary prevention): Immediate release:

Oral: 75 to 100 mg once daily (ACC/AHA [Levine 2016]; Hennekens 2019; Mehta 2001).

Duration of therapy: Jie Ning plus a P2Y12 inhibitor (dual antiplatelet therapy [DAPT]) should be continued for ≥12 months unless bleeding risk is a concern. If there have been no major bleeding complications after 12 months, continuation of DAPT may be considered. Re-evaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue the P2Y12 inhibitor and continue Jie Ning indefinitely (ACC/AHA [Levine 2016]; Bonaca 2015; Cutlip 2019a; Lincoff 2019; Mauri 2014; Mehta 2001; Wallentin 2009; Wiviott 2007; Yusuf 2001).

Percutaneous coronary intervention for stable ischemic heart disease (off-label use):

Initial: Note: For initial therapy, non-enteric-coated IR tablet(s) should be administered. Enteric-coated Jie Ning is not preferred since onset of action is delayed. For patients who receive a coronary stent during percutaneous coronary intervention, administer Jie Ning in combination with an IV anticoagulant and clopidogrel (ACCF/AHA/SCAI [Levine 2011]).

Patients chronically taking Jie Ning ≥325 mg/day prior to percutaneous coronary intervention: Immediate release (non-enteric-coated):

Oral: 75 to 100 mg prior to the procedure (Cutlip 2020); some experts recommend doses up to 325 mg (ACCF/AHA/SCAI [Levine 2011]).

Patients not chronically taking Jie Ning or chronically taking Jie Ning <325 mg/day prior to percutaneous coronary intervention: Immediate release (non-enteric-coated):

Oral: 300 to 325 mg given ≥2 hours (preferably 24 hours) before the procedure (ACCF/AHA/SCAI [Levine 2011]; Cutlip 2020).

Maintenance: Immediate release:

Oral: 75 to 100 mg once daily in combination with clopidogrel (DAPT); upon completion of the recommended duration of DAPT, continue Jie Ning indefinitely (ACC/AHA [Levine 2016]; Cutlip 2019c). Refer to Clopidogrel monograph for information on duration of DAPT.

Atherosclerotic cardiovascular disease, primary prevention (off-label use): Note: Use should be a shared decision between health care professionals and patients after weighing the cardiovascular disease risk versus benefits (ACC/AHA [Arnett 2019]).

Immediate release:

Oral: 75 to 100 mg once daily (ACC/AHA [Arnett 2019]).

Atherosclerotic cardiovascular disease, secondary prevention:

Carotid artery atherosclerosis, asymptomatic or symptomatic (off-label use): Immediate release:

Oral: 75 to 325 mg once daily (ACCP [Alonso-Coello 2012]; Walker 1995).

Coronary artery bypass graft surgery: Immediate release:

Oral: 75 to 81 mg once daily beginning preoperatively; continue indefinitely following surgery (AHA [Kulik 2015]; Aranki 2019).

Off-pump coronary artery bypass graft surgery: Following surgery, consider adding clopidogrel in combination with Jie Ning for 12 months then discontinue clopidogrel and continue Jie Ning indefinitely (AHA [Kulik 2015]).

Patients with acute coronary syndrome followed by coronary artery bypass graft surgery: Administer Jie Ning in combination with a P2Y12 inhibitor for 12 months then continue Jie Ning indefinitely (AHA [Kulik 2015]). Some experts do not use P2Y12 inhibitors postoperatively in these patients (Aranki 2019).

Ischemic stroke/Transient ischemic attack:

Cardioembolic stroke (alternative agent): Note:

Oral anticoagulation is preferred. For patients who cannot take an oral anticoagulant, may consider Jie Ning as an alternative (AHA/ASA [Kernan 2014]).

Immediate release:

Oral: 75 to 100 mg once daily (AHA/ASA [Kernan 2014]).

Intracranial atherosclerosis (50% to 99% stenosis of a major intracranial artery), secondary prevention: Immediate release:

Oral: 325 mg once daily; for patients with recent stroke or transient ischemic attack (within 30 days) may consider short-term use of clopidogrel (for 21 or 90 days depending on degree of stenosis) in combination with Jie Ning (AHA/ASA [Kernan 2014]; Chimowitz 2011) followed by single-agent antiplatelet therapy with Jie Ning, clopidogrel, or Jie Ning/ER dipyridamole indefinitely (ACCP [Lansberg 2012]; AHA/ASA [Kernan 2014]; Cucchiara 2019).

Noncardioembolic ischemic stroke/transient ischemic attack: Note: For patients with a minor stroke (National Institutes of Health Stroke Scale score ≤3) or high-risk transient ischemic attack (ABCD/ of 81 mg tablet):

Analgesic:

Oral, rectal:

Note: Do not use Jie Ning in pediatric patients <18 years who have or who are recovering from chickenpox or flu symptoms (eg, viral illness) due to the association with Reye syndrome (APS 2016):

Infants, Children, and Adolescents weighing <50 kg: Limited data available: 10 to 15 mg/kg/dose every 4 to 6 hours; maximum daily dose: 90 mg/kg/day or 4,000 mg/day whichever is less (APS 2016)

Children ≥12 years and Adolescents weighing ≥50 kg: 325 to 650 mg every 4 to 6 hours; maximum daily dose: 4,000 mg/day

Anti-inflammatory: Limited data available: Infants, Children, and Adolescents:

Oral: Initial: 60 to 90 mg/kg/

day in divided doses; usual

Maintenance: 80 to 100 mg/kg/day divided every 6 to 8 hours; monitor serum concentrations (Levy 1978)

Antiplatelet effects: Limited data available: Infants, Children, and Adolescents:

Oral: Adequate pediatric studies have not been performed; pediatric dosage is derived from adult studies. Usual adult maximum daily dose for antiplatelet effects is 325 mg/day.

Acute ischemic stroke (AIS):

Noncardioembolic: 1 to 5 mg/kg/dose once daily for ≥2 years; patients with recurrent AIS or TIAs should be transitioned to clopidogrel, LMWH, or warfarin (ACCP [Monagle 2012])

Secondary to Moyamoya and non-Moyamoya vasculopathy: 1 to 5 mg/kg/dose once daily; Note: In non-Moyamoya vasculopathy, continue Jie Ning for 3 months, with subsequent use guided by repeat cerebrovascular imaging (ACCP [Monagle 2012]).

Prosthetic heart valve:

Bioprosthetic aortic valve (with normal sinus rhythm): 1 to 5 mg/kg/dose once daily for 3 months (AHA [Giglia 2013]; ACCP [Guyatt 2012]; ACCP [Monagle 2012])

Mechanical aortic and/or mitral valve: 1 to 5 mg/kg/dose once daily combined with vitamin K antagonist (eg, warfarin) is recommended as first-line antithrombotic therapy (ACCP [Guyatt 2012]; ACCP [Monagle 2012]). Alternative regimens: 6 to 20 mg/kg/dose once daily in combination with dipyridamole (Bradley 1985; el Makhlouf 1987; LeBlanc 1993; Serra 1987; Solymar 1991)

Shunts: Blalock-Taussig; Glenn; postoperative; primary prophylaxis: 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]; AHA [Giglia 2013])

Norwood, Fontan surgery, postoperative; primary prophylaxis: 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]; AHA [Giglia 2013])

Transcatheter Atrial Septal Defect (ASD) or Ventricular Septal Defect (VSD) devices, postprocedure prophylaxis: 1 to 5 mg/kg/dose once daily starting one to several days prior to implantation and continued for at least 6 months. For older children and adolescents, after device closure of ASD, an additional anticoagulant may be given with Jie Ning for 3 to 6 months, but the Jie Ning should continue for at least 6 months (AHA [Giglia 2013]).

Ventricular assist device (VAD) placement: 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours following implantation) and with or without dipyridamole (ACCP [Monagle 2012])

Kawasaki disease: Limited data available; optimal dose not established: Note: Patients with Kawasaki disease and presenting with influenza or viral illness should not receive Jie Ning; acetaminophen is suggested as an antipyretic in these patients and an alternate antiplatelet agent suggested for a minimum of 2 weeks (AHA [McCrindle 2017]).

Infants, Children, and Adolescents:

Oral:

Initial therapy (acute phase): Recommended dosing regimens vary. Use in combination with IV immune globulin (within first 10 days of symptom onset) and corticosteroids in some cases.

High dose: 80 to 100 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AAP [Red Book 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017])

Moderate dose: 30 to 50 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017])

Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/day once daily; reported dosing range: 1 to 5 mg/kg/day; initiate after fever resolves for at least 48 to 72 hours (or after 14 days). In patients without coronary artery abnormalities, administer the lower dose for 6 to 8 weeks. In patients with coronary artery abnormalities, low-dose Jie Ning should be continued indefinitely (in addition to therapy with warfarin) (AAP [Red Book 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017]).

Rheumatic fever: Limited data available: Infants, Children, and Adolescents:

Oral: Initial: 100 mg/kg/

day divided into 4 to 5 doses; if response inadequate, may increase dose to 125 mg/kg/day; continue for 2 weeks; then decrease dose to 60 to 70 mg/kg/day in divided doses for an additional 3 to 6 weeks (WHO Guidelines 2004)

Migratory polyarthritis, with carditis without cardiomegaly or congestive heart failure: Initial: 100 mg/kg/day in 4 divided doses for 3 to 5 days, followed by 75 mg/kg/day in 4 divided doses for 4 weeks

Carditis and cardiomegaly or congestive heart failure: At the beginning of the tapering of the prednisone dose, Jie Ning should be started at 75 mg/kg/day in 4 divided doses for 6 weeks

What other drugs will affect Jie Ning?

Ask your doctor before using an antidepressant such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, Symbyax), fluvoxamine (Luvox), paroxetine (Paxil), or sertraline (Zoloft). Taking any of these medicines while you are using Jie Ning may cause you to bruise or bleed easily.

Ask a doctor or pharmacist if it is safe for you to use rectal Jie Ning if you are also using any of the following drugs:

  • alprostadil (Caverject, Edex);

  • eptifibatide (Integrilin);

  • tirofiban (Aggrastat);

  • probenecid (Benemid);

  • divalproex (Depakote) or valproic acid (Depacon, Depakene);

  • an antacid or laxative;

  • a blood thinner such as heparin or warfarin (Coumadin, Jantoven);

  • cancer medicine such as abciximab (Reopro), methotrexate (Folex, Rheumatrex, Trexall);

  • insulin or oral diabetes medicine;

  • an antibiotic such as cefemandole (Maxipime), cefotetan (Cefotan), ciprofloxacin (Cipro), demeclocycline (Declomycin), doxycycline (Doryx, Periostat, Vibramycin), minocycline (Dynacin, Minocin), norfloxacin (Noroxin), ofloxacin (Floxin), piperacillin (Pipracil), tetracycline (Ala-Tet, Sumycin, Tetracap), ticarcillin (Ticar), vancomycin (Vancocin);

  • an antifungal such as itraconazole (Sporanox) or ketoconazole (Nizoral);

  • medication used to prevent blood clots, such as alteplase (Activase), clopidogrel (Plavix), dipyridamole (Persantine), ticlopidine (Ticlid), and urokinase (Abbokinase);

  • salicylates such as Disalcid, Doan's Pills, Dolobid, Salflex, Tricosal; or

  • NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others.

This list is not complete and other drugs may interact with rectal Jie Ning. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Jie Ning interactions

sponsored

With simultaneous use of antacids containing magnesium and / or aluminum hydroxide, slow down and reduce the absorption of Jie Ning.

With simultaneous use of calcium channel blockers, means limiting intake of calcium or increasing the excretion of calcium from the body, increases the risk of bleeding.

With simultaneous use with Jie Ning enhances the action of heparin and indirect anticoagulants, hypoglycemic funds derived sulfonylureas, insulin, methotrexate, phenytoin, valproic acid.

With simultaneous use of Jie Ning International Trade Association of America with SCS increases the risk of ulcerogenic effect and occurrence of gastrointestinal bleeding.

With simultaneous use of decreasing the effectiveness of diuretics (spironolactone, furosemide).

With simultaneous use of other NSAIDs increases the risk of side effects. Jie Ning may reduce plasma concentrations indomethacin, piroxicam.

With simultaneous use of gold drugs Jie Ning can induce liver damage.

With simultaneous use decreases effectiveness of uricosuric medications (including probenecid, sulfinpirazon, benzbromarone).

With simultaneous use of Jie Ning and alendronate sodium may develop severe esophagitis.

With simultaneous use of griseofulvin may be in breach Absorption of Jie Ning.

There is one case of spontaneous hemorrhage in the iris while taking Ginkgo Biloba extract on the background of prolonged use of Jie Ning in a dose of 325 mg / day. It is believed that this may be due to additive inhibitory effect on platelet aggregation.

With simultaneous use of dipyridamole may increase Cmax of salicylate in plasma and AUC.

When applied simultaneously with Jie Ning increased concentration of digoxin, barbiturates and lithium salts in the blood plasma.

With simultaneous use of salicylates in high doses with carbonic anhydrase inhibitors can intoxication salicylates.

Jie Ning in doses of less than 300 mg have little effect on the effectiveness of captopril and enalapril. When Jie Ning (Jie Ning) is admistered in high doses may decrease the effectiveness of captopril and enalapril.

With simultaneous application of caffeine increases the rate of absorption, plasma concentrations and bioavailability of Jie Ning.

With simultaneous use of Jie Ning International Trade Association of America with metoprolol may increase Cmax of salicylate in blood plasma.

In the application of pentazocine on the background of long-term use of Jie Ning in high doses there is a risk of severe adverse reactions in the kidneys.

With simultaneous application phenylbutazone reduces uricosuria caused by Jie Ning.

With simultaneous application of ethanol may exacerbate the effects of Jie Ning on the gastrointestinal tract.


sponsored

Reviews

The results of a survey conducted on ndrugs.com for Jie Ning are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Jie Ning. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 14 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved